Forescout Addresses Modern SecOps Challenges with Launch of Forescout XDR
1.3.2023 18:00:00 EET | Business Wire | Press release
Forescout Technologies Inc., the global leader in automated cybersecurity, today unveiled Forescout XDR, to help enterprises better detect, investigate, and respond to the broadest range of advanced threats, across the extended enterprise.
A typical SOC is flooded with 450 alerts per hour1, and analysts waste precious time trying to correlate low fidelity alerts and chasing false positives, often at the expense of focusing on legitimate attacks. Until now, a security operations center’s (SOC) field of view for threat detection and response has excluded critical devices that are increasingly common points of attack, including operational technology (OT), industrial control systems (ICS), building management systems (BMS), and medical and IoT devices. In addition, the technology stack that SecOps teams have had to rely on has made it difficult to respond to these threats in a rapid and comprehensive manner.
“The true value of an XDR solution lies in its ability to ingest telemetry and data from across the entire enterprise: cloud, campus, remote and datacenter environments, and every managed and unmanaged connected device. This is what the X in XDR is all about, after all,” said Justin Foster, CTO, Forescout. “Traditional XDR products lack this capability, or they only leverage data from the vendor’s own EDR or a few other security tools. This significantly limits the flexibility, scalability and effectiveness that an XDR solution must provide.”
Through the advanced application of data science and automation, Forescout XDR generates one high-fidelity alert that truly warrants analyst investigation, from every 50 million logs ingested, per hour2. Because Forescout XDR is vendor- and EDR-agnostic, this ingestion includes data from over 170 security, infrastructure, application, cloud/SaaS and enrichment sources, and dozens of leading vendors. And with over 70 sources of threat intelligence and 1500 verified detection rules and models, and data onboarding included, Forescout XDR customers can be operational within hours, actively detecting, investigating, and responding to threats.
“Forescout XDR, with the breadth and richness of its capabilities, particularly its dashboards and reporting, provides an out-of-the-box solution to SOC challenges that we spent 18-24 months trying to address,” said Samer Mansour, CISO, Panasonic Corporation of North America. “It was easy to deploy, and fully operational in a matter of weeks. And with its tight integration to Forescout’s network security and visibility solutions, and our broader security tech stack, it gives us the ability to exert a lot more control across our IT and OT environments, and further elevate our overall security.”
Seamless integration with Forescout’s industry-leading network access control solution helps ensure that customers can:
- Reduce the attack surface, and the risk of an attack in the first place, by preventing compromised or non-compliant devices from connecting to their networks. This proactive approach to XDR further elevates the effectiveness and performance of a modern SOC.
- Automate response workflows that can immediately touch every managed and unmanaged connected device, across the enterprise. This reduces an attack's blast radius in real-time, allowing proper mitigation or remediation measures to be completed.
Because Forescout XDR has a multi-tenant architecture and supports local data storage while also being able to provide an aggregated global view of threats and SOC performance, it is ideally suited to large enterprises, multi-nationals, organizations with regional SOCs and managed security service providers (MSSPs).
Pricing
SaaS licensing is based on the total number of endpoints in the enterprise. As such, customers have the flexibility to leverage the data sources needed to fully support the use cases important to them, and help ensure better detection, without concern for escalating or fluctuating costs associated with cloud log storage.
About Forescout
Forescout Technologies, Inc. delivers automated cybersecurity across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types- IT, IoT, OT, IoMT, and cloud environments. The Forescout Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com
Managing cyber risk, together.
|
1 |
“The 2020 State of Security Operations,” Forrester Consulting |
|
|
2 |
Based on aggregate Forescout data from a 1-year period (Dec 2021-2022), across 30 enterprise customers, representing a range of company sizes and industries. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005455/en/
Contact information
Media Contact:
Emily Alfano
Manager of PR
Emily.alfano@forescout.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
